| Literature DB >> 28490944 |
R Rajakrishnan1, R Lekshmi2, P B Benil3, J Thomas1, A H AlFarhan1, V Rakesh1, S Khalaf1.
Abstract
Search for medicinal plants to treat kidney disorders is an important topic on phytotherapeutical research. Plumbago zeylanica L. is an important medicinal plant with hepatoprotective, anti-inflammatory, anti-diabetic, anti-cancer and anti-hyperlipidemic activities. In the present study, the protective effect of hydroalcoholic extract of P. zeylanica (HAPZ) in cisplatin induced nephrotoxicity was analyzed in Swiss albino mice. Treatment with higher dose (400 mg/kg) of HAPZ significantly reversed the adverse effect of cisplatin on kidney weight, serum urea and creatinine, indicating their renoprotective effect. The antioxidant effect of the drug is evident from its significant effect on Catalase, Glutathione peroxidase and lipid peroxidation activities.Entities:
Keywords: Cisplatin; Histopathology; Lipid peroxidation; Nephrotoxicity; Phytochemical screening
Year: 2017 PMID: 28490944 PMCID: PMC5415120 DOI: 10.1016/j.sjbs.2017.01.001
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.219
Figure 1Plumbago zeylanica (A) Habit; (B) Dried root; (C) Powdered root.
Preliminary phytochemical screening of roots of P. zeylanica successive extracts.
| Pet ether | Chloroform | Ethyl acetate | Methanol | |
|---|---|---|---|---|
| Alkaloid | − | − | + | + |
| Carbohydrate | − | + | + | + |
| Carboxylic acid | − | − | − | − |
| Coumarins | − | − | − | − |
| Flavanoids | − | − | − | + |
| Phenol | − | − | + | − |
| Quinone | − | + | − | − |
| Resins | − | − | − | − |
| Steroid | + | + | + | + |
| Saponins | − | − | − | − |
| Tannin | − | − | + | + |
| Terpenoid | − | + | − | − |
List of phytochemicals identified by GC–MS of diethyl ether extract of roots of P. zeylanica.
| Peak | RT | % Area | Name | Match |
|---|---|---|---|---|
| 1 | 13.050 | 14.08 | β-Asarone | Identified |
| 2 | 13.225 | 40.09 | 1,4-Naphthalenedione | Identified |
| 3 | 13.657 | 2.31 | – | Unidentified |
| 4 | 13.857 | 4.58 | Ethyl | Identified |
| 5 | 14.720 | 2.18 | n-hexadecanoic acid | Identified |
| 6 | 14.764 | 9.13 | – | Unidentified |
| 7 | 14.945 | 7.68 | Naphtho(2,3-b)furan-2(3H)-one | Identified |
| 8 | 15.546 | 19.95 | Oleic Acid | Identified |
Figure 2GC–MS of diethyl ether extract of roots of P. zeylanica.
Effects of HAPZ on Kidney weight, Serum urea, Serum creatinine, Serum uric acid, Serum sodium and potassium.
| Groups | Kidney weight (mg) | Urea (mg/dl) | Creatinine (mg/dl) | Uric acid (mg/dl) | Sodium (mmol/L) | Potassium (mmol/L) |
|---|---|---|---|---|---|---|
| Normal Control | 318.00 ± 7.92 | 40.67 ± 1.58 | 0.7 ± 0.05 | 2 ± 0.13 | 146.00 ± 2.26 | 5.18 ± 0.26 |
| Cisplatin control | 479.00 ± 15.68## | 133.67 ± 2.06### | 3.0 ± 0.19### | 3.63 ± 0.23# | 148.5 ± 1.04 | 3.50 ± 0.24# |
| HAPZ 200 | 465.71 ± 24.66 | 42.50 ± 1.94*** | 0.85 ± 0.06** | 2.48 ± 0.40 | 144.00 ± 1.09 | 5.00 ± 0.36 |
| HAPZ 400 | 375.00 ± 13.38** | 47.17 ± 2.98*** | 1.08 ± 0.10** | 2.78 ± 0.18 | 141.00 ± 0.88* | 5.23 ± 0.19* |
Data: MEAN ± SEM, ###P < 0.001 in comparison to normal control group, ##P < 0.01 in comparison to normal control group, #P < 0.05 in comparison to cisplatin control group, ***P < 0.001 in comparison to cisplatin control group, **P < 0.01 in comparison to cisplatin control group, *P < 0.05 in comparison to cisplatin control group.
Effect of HASA and HAPZ on antioxidant parameters.
| Groups | Catalase (μM of H2O2 consumed/min/mg protein) | Glutathione peroxidase (μM of GSH oxidized/min/mg protein) | Lipid peroxidation(μM of MDA formed/g wet tissue) |
|---|---|---|---|
| Group I | 98.34. ± 1.37 | 12.04. ± 0.65 | 26.98 ± 3.05 |
| Group II | 16.63 ± 2.48### | 3.08 ± 0.63## | 160.99 ± 8.78### |
| Group III | 86.39 ± 2.93** | 8.76 ± 0.97** | 39.95 ± 7.92*** |
| Group IV | 77.95 ± 1.91** | 13.60 ± 0.54** | 45.33 ± 8.92** |
Data: MEAN ± SEM, ###P < 0.001 in comparison to normal control group, ##P < 0.01 in comparison to normal control group, ***P < 0.001 in comparison to cisplatin control group, **P < 0.01 in comparison to cisplatin control group.
Figure 3Histopathological examinations in the kidney tissue sections of mice of different groups (A) Normal control; (B) Cisplatin control; (C) HAPZ 200 mg/kg treated and (D) HAPZ 400 mg/kg treated.